The Institute for Clinical and Economic Review (ICER) on Tuesday, Feb. 25, released its final report on three acute treatments for migraine.
ICER reviewed Eli Lilly’s Reyvow, Biohaven’s rimegepant and Allergan’s Ubrelvy.
“For patients who are unable to take triptans or who don’t get adequate benefit from those more affordable options, these new migraine therapies appear to relieve migraine symptoms in 10-20% more patients than who respond to placebo,” ICER CMO David Rind said in a statement.
To read the final report, click here.
